| Characteristics | Number | Percent | Characteristics | Number | Percent |
| Age (years) |
|
| T |
|
|
| Mean ± SD | 50.23 ± 11.99 |
| T1 | 8 | 16% |
| Median Range | 50 (35 - 75) |
| T2 | 10 | 20% |
| ≤55 years | 18 | 36% | T3 | 22 | 44% |
| >55 years | 32 | 64% | T4 | 10 | 20% |
| Pathological type |
|
| Lymph node |
|
|
| IDC | 39 | 78% | Negative | 18 | 36% |
| Other | 11 | 22% | Positive | 32 | 64% |
| Grade |
|
| N |
|
|
| Grade I | 7 | 14% | N0 | 18 | 36% |
| Grade II | 13 | 26% | N1 | 6 | 12% |
| Grade III | 30 | 60% | N2 | 16 | 32% |
|
|
|
| N3 | 10 | 20% |
| ER |
|
| M |
|
|
| Negative | 20 | 40% | M0 | 40 | 80% |
| Positive | 30 | 60% | M1 | 10 | 20% |
| PR |
|
| AJCC Stage group |
|
|
| Negative | 22 | 45% | Stage I | 8 | 16% |
| Positive | 28 | 55% | Stage II | 10 | 20% |
| HER2/neu |
|
| Stage III | 22 | 44% |
| Negative | 30 | 40% | Stage IV | 10 | 20% |
| Positive | 20 | 60% |
|
|
|
| Ki-67 |
|
| FOXC2 |
|
|
| low | 20 | 40% | Low | 20 | 40% |
| high | 30 | 60% | High | 30 | 60% |
| Molecular type |
|
| YKL-40 |
|
|
| Luminal A | 10 | 20% | Low | 23 | 46% |
| Luminal B | 10 | 20% | High | 27 | 54% |
| HER2 amplified | 20 | 40% |
|
|
|
| Triple -ve | 10 | 20% |
|
|
|
|
|
|
| Follow-up (months) |
|
|
|
|
|
| Mean ± SD | 28.31 ± 7.27 |
|
|
|
|
| Median (Range) | 30 (15 - 36) |
|
|
|
|
| Outcome |
|
|
|
|
|
| Disease free | 30/34 | 84.1% |
|
|
|
| Local recurrence (LR) | 7/34 | 15.9% |
|
|
|
| Died | 13/50 | 38.3% |